¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ºÐÀÚ À¯Çüº°, Áúȯº°, ÀǾàǰ À¯Çüº°, ÀǾàǰ °³¹ß À¯Çüº°, Á¦Á¦º°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1701279
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 225 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 7,408¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ°ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2030³âÀÇ CAGRÀº 8.87%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤¹Ð ÀÇÇÐÀ» À§ÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Ã¤Åà Áõ°¡, ¹ÙÀÌ¿À Á¦Á¶ ±â¼úÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº °·ÂÇÑ ¿¬±¸ °³¹ß ÅõÀÚ, »õ·Î¿î »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ±ÔÁ¦ ½ÂÀÎ, ¹ÙÀÌ¿À½Ã¹Ð·¯ äÅà Ȯ´ë¿¡ ÀÇÇØ ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ´ÜÀÏ Å¬·Ð Ç×ü, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á¹ý, ÀçÁ¶ÇÕ ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ, Èñ±ÍÁúȯ Àü¹Ý¿¡ °ÉÃÄ Ä¡·á Á¢±Ù¹ýÀÌ ÀçÆíµÇ°í ÀÖ½À´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷ÀÇ ÆÄÀÌÇÁ¶óÀÎÀº À¯ÀüÀÚ Ä¡·á, RNA ±â¹Ý Ä¡·áÁ¦, ¿©·¯ ÀûÀÀÁõÀ» ´ë»óÀ¸·Î ÇÏ´Â ÀÌÁ߯¯À̼º Ç×ü¿¡ ´ëÇÑ ¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ¸é¼ °ß°íÇÏ°Ô À¯ÁöµÇ°í ÀÖ½À´Ï´Ù.
2024³â 12¿ù, ¹ÙÀÌ¿ÀÁ¨°ú »ï¼º¹ÙÀÌ¿À¿¡Çǽº´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ¾Æ´Þ¸®¹«¸¿¿¡ ´ëÇÑ EMA ½ÂÀÎÀ» ȹµæÇÏ¿© ÀÚ°¡¸é¿ªÁúȯ Ä¡·á ºÐ¾ßÀÇ ½ÃÀå °æÀïÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àû ¿òÁ÷ÀÓÀº Àü ¼¼°èÀûÀ¸·Î ¹ÙÀÌ¿À½Ã¹Ð·¯ µµÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °æÁ¦¼º ¹®Á¦¸¦ ÇØ°áÇÏ°í °íǰÁú »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ °ÍÀÔ´Ï´Ù.
°Ô´Ù°¡ ÇÇÇÏ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Ãâ½Ã´Â ȯÀÚ Ä¡·á °æÇèÀ» Çõ½ÅÇÏ¿© Æí¸®ÇÑ Åõ¿©¸¦ Á¦°øÇϰí ÁÖÀÔ ¼¾ÅÍ¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í ÀÖ½À´Ï´Ù.
¾÷°è ¹ßÀüÀÇ ÀÏȯÀ¸·Î 11¿ù 20ÀϺÎÅÍ 22ÀϱîÁö ½Ì°¡Æ÷¸£¿¡¼ °³ÃÖµÈ 2024 ¹ÙÀÌ¿À·ÎÁ÷½º Á¦Á¶ ÄÁÆÛ·±½º¿¡¼ Ç÷¡Æ¼³Ñ ½ºÆù¼·Î Âü°¡ÇÏ¿© ´ë±Ô¸ð ¹ÙÀÌ¿À·ÎÁ÷½º »ý»êÀÇ Çõ½Å¿¡ ÃÊÁ¡À» ¸ÂÃè½À´Ï´Ù. ÀÌ Çà»ç¿¡¼´Â ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ, °øÁ¤ °È, AI ±â¹Ý »ý¹°ÇÐÀû Á¦Á¦ °³¹ß µî Â÷¼¼´ë °íÈ¿´É Ä¡·áÁ¦¸¦ Çü¼ºÇÏ´Â ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ Æ®·»µå¸¦ ÁýÁß Á¶¸íÇß½À´Ï´Ù.
ÀÌ·¯ÇÑ Àü·«Àû ³ë·ÂÀº Àü ¼¼°èÀûÀ¸·Î ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ¹ÙÀÌ¿ÀÀǾàǰ Çõ½Å, ½ÃÀå È®´ë, ±ÔÁ¦ °³¼±¿¡ ´ëÇÑ Á߿伺ÀÌ Á¡Á¡ ´õ °Á¶µÇ°í ÀÖÀ½À» °Á¶ÇÕ´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
ºÐÀÚ À¯Çü¿¡ µû¶ó ´ÜÀÏŬ·ÐÇ×ü´Â ³ôÀº ƯÀ̼º, ±¤¹üÀ§ÇÑ Ä¡·á ÀÀ¿ë ºÐ¾ß, Á¾¾çÇÐ ¹× ÀÚ°¡¸é¿ªÁúȯ¿¡¼ÀÇ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2024³â ½ÃÀåÀ» Áö¹èÇϸç Àüü ¸ÅÃâÀÇ 61.05%¸¦ Â÷ÁöÇß½À´Ï´Ù.
Áúȯº°·Î´Â Á¾¾çÇÐÀº ¾Ï À¯º´·ü Áõ°¡¿Í »ý¹°ÇÐÀû Ä¡·á¹ý ½ÂÀÎ Áõ°¡·Î ÀÎÇØ 2024³â Àüü ½ÃÀåÀÇ 31.00%¸¦ Â÷ÁöÇÏ¸ç °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¸é¿ªÇÐ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀǾàǰ À¯Çüº°·Î, µ¶Á¡(ºê·£µå) ¹ÙÀÌ¿ÀÀǾàǰÀº Áö¼ÓÀûÀÎ R&D ÅõÀÚ¿Í °·ÂÇÑ Æ¯Çã º¸È£¿¡ ÈûÀÔ¾î 2024³â Àüü ½ÃÀåÀÇ 77.86%¸¦ Â÷ÁöÇÏ¸ç °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀǾàǰ °³¹ß À¯Çüº°·Î º¸¸é, ¾Æ¿ô¼Ò½Ì ¹ÙÀÌ¿ÀÀǾàǰ °³¹ßÀÌ 2024³â ½ÃÀåÀ» Áö¹èÇϸç Àüü ¸ÅÃâÀÇ 56.15%¸¦ Â÷ÁöÇÏ¸ç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
Á¦Á¦º°·Î´Â 2024³â¿¡´Â ÁÖ»çÇü »ý¹°ÇÐÀû Á¦Á¦(IV, IM, SC)°¡ Àü½Å Èí¼ö ¹× È¿°ú¿¡ ÈûÀÔ¾î ½ÃÀåÀÇ 92.55%¸¦ Â÷ÁöÇÏ¸ç °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Åõ¿© °æ·Îº°·Î´Â ºñ°æ±¸ Åõ¿©(IV, IM, SC)°¡ 2024³â 88.74%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ó¹æ À¯Çüº°·Î´Â ó¹æ ÀǾàǰÀº ¾ö°ÝÇÑ ±ÔÁ¦ °¨µ¶°ú »ý¹°ÇÐÀû Ä¡·áÀÇ º¹À⼺À¸·Î ÀÎÇØ 2024³â Àüü ¸ÅÃâÀÇ 96.90%¸¦ Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù.
À¯Åë ä³Îº°·Î´Â º´¿ø ¹× Àü¹® Ŭ¸®´ÐÀ» Æ÷ÇÔÇÑ ºñ¼Ò¸Å ä³ÎÀÌ 2024³â ÃÑ ¸ÅÃâÀÇ 55.70%¸¦ Â÷ÁöÇß½À´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷ÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â ¾ÏÁ¨(Amgen Inc.), ÈÀÌÀÚ(Pfizer Inc.), ³ë¹ÙƼ½º(Novartis AG), »ç³ëÇÇ(Sanofi), ¸ÓÅ©(Merck & Co.), ·Î½´ Ȧµù(Roche Holding AG), ¹ÙÀÌ¿ÀÁ¨(Biogen Inc.), ¾Æ½ºÆ®¶óÁ¦³×Ä«, À϶óÀÌ ¸±¸® ¾Ø ÄÄÆÛ´Ï, ¹ÙÀÌ¿¤ AG µîÀÌ ÀÖ½À´Ï´Ù.
2024³â 6¿ù, ¸®Á¦³×·Ð ÆÛ¸Ó½´Æ¼ÄÃÁîÀ×Å©´Â 2¼¼ ÀÌ»óÀÇ È°µ¿¼ºÀÇ ´Ù°üÀýÇü ÀþÀº¼º Ư¹ß¼º °üÀý¿°(pJIA)ÀÇ Ä¡·á·Î¼ ÄɺÎÀÚ¶ó(»ì¸±¸¶ºê)°¡ ¹Ì±¹ FDAº¸´Ù ½ÂÀÎµÈ °ÍÀ» ¹ßÇ¥Çß½À´Ï´Ù. À̹ø ½ÂÀÎÀ¸·Î ÀÌ ¸¸¼º ¿°Áõ¼º Áúȯ¿¡ °É¸° ¾î¸°ÀÌ¿¡°Ô »õ·Î¿î Ä¡·á ¿É¼ÇÀÌ Á¦°øµË´Ï´Ù. ¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅëÀÇ Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
ºñÁî´Ï½º ȯ°æ ºÐ¼®
»ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
PESTLE ºÐ¼®
ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
°¡°Ý ºÐ¼®
Á¦4Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : ºÐÀÚ À¯Çüº° ºñÁî´Ï½º ºÐ¼®
ºÐÀÚ À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
ºÐÀÚ À¯Çüº° ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(ºÐÀÚ À¯Çüº°, 2018-2030³â)
´ÜÀÏŬ·ÐÇ×ü
ÀÎÅÍÆä·Ð
Àν¶¸°
¼ºÀå ¹× ÀÀ°íÀÎÀÚ
¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾
¹é½Å
È£¸£¸ó
±âŸ
Á¦5Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : Áúȯº° ºñÁî´Ï½º ºÐ¼®
Áúȯ ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
Áúȯ ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(Áúȯº°, 2018-2030³â)
Á¾¾çÇÐ
Ç÷¾× Áúȯ
´ë»ç¼º Áúȯ
°¨¿°Áõ
½ÉÇ÷°ü Áúȯ
½Å°æÁúȯ
¸é¿ªÇÐ
±âŸ
Á¦6Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : ÀǾàǰ À¯Çüº° ºñÁî´Ï½º ºÐ¼®
ÀǾàǰ À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
ÀǾàǰ À¯Çü ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(ÀǾàǰ À¯Çüº°, 2018-2030³â)
µ¶Á¡ ºê·£µå
Á¦7Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : ÀǾàǰ °³¹ß À¯Çüº°, ºñÁî´Ï½º ºÐ¼®
ÀǾàǰ °³¹ß À¯Çü ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
ÀǾàǰ °³¹ß À¯Çü ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(ÀǾàǰ °³¹ß À¯Çüº°, 2018-2030³â)
¾Æ¿ô¼Ò½Ì
»ç³»
Á¦8Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : Á¦Á¦º° ºñÁî´Ï½º ºÐ¼®
Á¦Á¦ ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
Á¦Çü ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(Á¦Á¦º°, 2018-2030³â)
ÁÖ»çÁ¦(IV, IM, SC)
ÈíÀÔ ¹× ºñ°
±âŸ
Á¦9Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : Åõ¿© °æ·Îº° ºñÁî´Ï½º ºÐ¼®
Åõ¿© °æ·Î ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
Åõ¿© °æ·Î ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(Åõ¿© °æ·Îº°, 2018-2030³â)
ºñ°æ±¸(IV, IM, SC)
ÈíÀÔ ¹× ºñ°
±âŸ
Á¦10Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : ó¹æº° ºñÁî´Ï½º ºÐ¼®
ó¹æ À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
ó¹æ À¯Çü ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®(ó¹æ À¯Çüº°, 2018-2030³â)
ó¹æ ÀǾàǰ
½ÃÆÇ¾à(OTC)
Á¦11Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : À¯Åë ä³Îº° ºñÁî´Ï½º ºÐ¼®
À¯Åë ä³Î ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
À¯Åë ä³Î ºÎ¹® ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®(À¯Åëä³Îº°, 2018-2030³â)
¼Ò¸Å
ºñ¼Ò¸Å
Á¦12Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
ºÏ¹Ì
±¹°¡º°(2018-2030³â)
¹Ì±¹
ij³ª´Ù
¸ß½ÃÄÚ
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
½º¿þµ§
³ë¸£¿þÀÌ
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
ű¹
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
Äí¿þÀÌÆ®
Á¦13Àå °æÀï ±¸µµ
Âü°¡ÀÚ °³¿ä
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
±â¾÷ ºÐ·ù
Àü·« ¸ÅÇÎ
±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× »óÀå ±â¾÷
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Pfizer Inc.
Bristol-Myers Squibb Company
Sanofi
GSK plc.
AstraZeneca
Takeda Pharmaceutical Company Limited
Biogen
Eli Lilly and Company
Novo Nordisk A/S
Amgen Inc.
HBR
¿µ¹® ¸ñÂ÷
Biopharmaceutical Market Growth & Trends:
The global biopharmaceutical market size is anticipated to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.
The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.
In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.
Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie's subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.
As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20-22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.
These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.
Biopharmaceutical Market Report Highlights:
Based on molecule type, monoclonal antibodies dominated the market in 2024, accounting for 61.05% of the total revenue due to their high specificity, broad therapeutic applications, and growing demand in oncology and autoimmune disorders. The hormone segment is projected to grow at a robust CAGR over the forecast period, driven by increasing adoption in endocrinology and metabolic disease treatments.
Based on disease, oncology led the market with the largest revenue share in 2024, accounting for 31.00% of the total market due to the rising prevalence of cancer and increasing approvals of biologic therapies. However, the immunology segment is expected to grow at the fastest rate over the forecast period.
Based on drug type, proprietary (branded) biopharmaceuticals held the largest revenue share in 2024, comprising 77.86% of the total market, attributed to continuous R&D investments and strong patent protection. However, biosimilars are expected to witness the fastest CAGR over the forecast period due to regulatory approvals and increasing cost-saving initiatives.
Based on drug development type, outsourced biopharmaceutical development dominated the market in 2024, accounting for 56.15% of the total revenue as companies increasingly leverage contract development and manufacturing organizations (CDMOs) to optimize costs and accelerate commercialization.
Based on formulation, injectable biologics (IV, IM, SC) held the largest revenue share in 2024, comprising 92.55% of the market, driven by their systemic absorption and effectiveness. However, inhalation and nasal biologics are expected to witness significant growth due to advancements in non-invasive drug delivery.
Based on route of administration, parenteral administration (IV, IM, SC) led the market in 2024, with an 88.74% share, as most biologics require systemic delivery. Inhalation and nasal routes are expected to gain traction over the forecast period.
Based on prescription type, prescription medicines dominated the market in 2024, accounting for 96.90% of the total revenue due to stringent regulatory oversight and the complexity of biologic therapies.
Based on sales channel, non-retail channels, including hospitals and specialty clinics, emerged as the dominant distribution channel in 2024, accounting for 55.70% of total revenue, reflecting the need for controlled administration and storage of biologics.
Key players operating in the biopharmaceutical industry include Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi; Merck & Co.; Roche Holding AG; Biogen Inc.; AstraZeneca; Eli Lilly and Company; and Bayer AG.
In June 2024, Regeneron Pharmaceuticals, Inc. announced the approval of Kevzara (sarilumab) by the U.S. FDA for the treatment of active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years and older. This approval provides a new treatment option for children affected by this chronic inflammatory condition.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule Type
1.2.2. Disease
1.2.3. Drug Type
1.2.4. Drug Development Type
1.2.5. Formulation
1.2.6. Route of Administration
1.2.7. Prescription Type
1.2.8. Sales Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR's Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis
4.1. Molecule Type Market Share, 2024 & 2030
4.2. Molecule Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type , 2018 to 2030 (USD Million)
4.4. Monoclonal Antibody
4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
4.5. Interferon
4.5.1. Interferon Market, 2018 - 2030 (USD Million)
4.6. Insulin
4.6.1. Insulin Market, 2018 - 2030 (USD Million)
4.7. Growth and Coagulation Factor
4.7.1. Growth and Coagulation Factor Market, 2018 - 2030 (USD Million)
4.8. Erythropoietin
4.8.1. Erythropoietin Market, 2018 - 2030 (USD Million)
4.9. Vaccine
4.9.1. Vaccine Market, 2018 - 2030 (USD Million)
4.10. Hormone
4.10.1. Hormone Market, 2018 - 2030 (USD Million)
4.11. Others
4.11.1. Other Type Market, 2018 - 2030 (USD Million)
Chapter 5. Biopharmaceutical Market: Disease Business Analysis
5.1. Disease Market Share, 2024 & 2030
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology Market, 2018 - 2030 (USD Million)
5.5. Blood Disorder
5.5.1. Blood Disorder Market, 2018 - 2030 (USD Million)
5.6. Metabolic Disease
5.6.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
5.7. Infectious Disease
5.7.1. Infectious Disease Market, 2018 - 2030 (USD Million)
5.8. Cardiovascular Disease
5.8.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
5.9. Neurological Disease
5.9.1. Neurological Disease Market, 2018 - 2030 (USD Million)
5.10. Immunology
5.10.1. Immunology Market, 2018 - 2030 (USD Million)
5.11. Others
5.11.1. Other Type Market, 2018 - 2030 (USD Million)
Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis
6.1. Drug Type Market Share, 2024 & 2030
6.2. Drug Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
6.4. Proprietary (Branded)
6.4.1. Proprietary (Branded) Market, 2018 - 2030 (USD Million)
6.4.2. Biosimilars
6.4.2.1. Biosimilars Market, 2018 - 2030 (USD Million)
Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis
7.1. Drug Development Type Market Share, 2024 & 2030
7.2. Drug Development Type Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2018 to 2030 (USD Million)
7.4. Outsource
7.4.1. Outsource Market, 2018 - 2030 (USD Million)
7.5. In-house
7.5.1. In-house Market, 2018 - 2030 (USD Million)
Chapter 8. Biopharmaceutical Market: Formulation Business Analysis
8.1. Formulation Market Share, 2024 & 2030
8.2. Formulation Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
8.4. Injectables (IV, IM, SC)
8.4.1. Injectables (IV, IM, SC) Market, 2018 - 2030 (USD Million)
8.5. Inhalation/Nasal Sprays
8.5.1. Inhalation/Nasal Sprays Market, 2018 - 2030 (USD Million)
8.6. Other Formulations
8.6.1. Other Formulations Market, 2018 - 2030 (USD Million)
Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis
9.1. Route of Administration Market Share, 2024 & 2030
9.2. Route of Administration Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
9.4. Parenteral (IV, IM, SC)
9.4.1. Parenteral (IV, IM, SC) Market, 2018 - 2030 (USD Million)
9.5. Inhalation/Nasal
9.5.1. Inhalation/Nasal Market, 2018 - 2030 (USD Million)
9.6. Other Routes
9.6.1. Other Routes Market, 2018 - 2030 (USD Million)
Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis
10.1. Prescription Type Market Share, 2024 & 2030
10.2. Prescription Type Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2018 to 2030 (USD Million)
10.4. Prescription Medicines
10.4.1. Prescription Medicines Market, 2018 - 2030 (USD Million)
10.5. Over-the-counter (OTC) Medicines
10.5.1. Over-the-counter (OTC) Medicines Market, 2018 - 2030 (USD Million)
Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis
11.1. Sales Channel Market Share, 2024 & 2030
11.2. Sales Channel Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
11.4. Retail Pharmacies
11.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
11.5. Non-retail
11.5.1. Non-retail Market, 2018 - 2030 (USD Million)
Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis
12.1. Regional Market Share Analysis, 2024 & 2030
12.2. Regional Market Dashboard
12.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
12.4. North America
12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
12.4.2. U.S.
12.4.2.1. Key Country Dynamics
12.4.2.2. Target Disease Prevalence
12.4.2.3. Regulatory Framework
12.4.2.4. Reimbursement Framework
12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.3. Canada
12.4.3.1. Key Country Dynamics
12.4.3.2. Target Disease Prevalence
12.4.3.3. Regulatory Framework
12.4.3.4. Reimbursement Framework
12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.4. Mexico
12.4.4.1. Key Country Dynamics
12.4.4.2. Target Disease Prevalence
12.4.4.3. Regulatory Framework
12.4.4.4. Reimbursement Framework
12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5. Europe
12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.2. UK
12.5.2.1. Key Country Dynamics
12.5.2.2. Target Disease Prevalence
12.5.2.3. Regulatory Framework
12.5.2.4. Reimbursement Framework
12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.3. Germany
12.5.3.1. Key Country Dynamics
12.5.3.2. Target Disease Prevalence
12.5.3.3. Regulatory Framework
12.5.3.4. Reimbursement Framework
12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.4. France
12.5.4.1. Key Country Dynamics
12.5.4.2. Target Disease Prevalence
12.5.4.3. Regulatory Framework
12.5.4.4. Reimbursement Framework
12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.5. Italy
12.5.5.1. Key Country Dynamics
12.5.5.2. Target Disease Prevalence
12.5.5.3. Regulatory Framework
12.5.5.4. Reimbursement Framework
12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.6. Spain
12.5.6.1. Key Country Dynamics
12.5.6.2. Target Disease Prevalence
12.5.6.3. Regulatory Framework
12.5.6.4. Reimbursement Framework
12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.7. Denmark
12.5.7.1. Key Country Dynamics
12.5.7.2. Target Disease Prevalence
12.5.7.3. Regulatory Framework
12.5.7.4. Reimbursement Framework
12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.8. Sweden
12.5.8.1. Key Country Dynamics
12.5.8.2. Target Disease Prevalence
12.5.8.3. Regulatory Framework
12.5.8.4. Reimbursement Framework
12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.9. Norway
12.5.9.1. Key Country Dynamics
12.5.9.2. Target Disease Prevalence
12.5.9.3. Regulatory Framework
12.5.9.4. Reimbursement Framework
12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6. Asia Pacific
12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.2. Japan
12.6.2.1. Key Country Dynamics
12.6.2.2. Target Disease Prevalence
12.6.2.3. Regulatory Framework
12.6.2.4. Reimbursement Framework
12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.3. China
12.6.3.1. Key Country Dynamics
12.6.3.2. Target Disease Prevalence
12.6.3.3. Regulatory Framework
12.6.3.4. Reimbursement Framework
12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.4. India
12.6.4.1. Key Country Dynamics
12.6.4.2. Target Disease Prevalence
12.6.4.3. Regulatory Framework
12.6.4.4. Reimbursement Framework
12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.5. Australia
12.6.5.1. Key Country Dynamics
12.6.5.2. Target Disease Prevalence
12.6.5.3. Regulatory Framework
12.6.5.4. Reimbursement Framework
12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.6. South Korea
12.6.6.1. Key Country Dynamics
12.6.6.2. Target Disease Prevalence
12.6.6.3. Regulatory Framework
12.6.6.4. Reimbursement Framework
12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.7. Thailand
12.6.7.1. Key Country Dynamics
12.6.7.2. Target Disease Prevalence
12.6.7.3. Regulatory Framework
12.6.7.4. Reimbursement Framework
12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7. Latin America
12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.2. Brazil
12.7.2.1. Key Country Dynamics
12.7.2.2. Target Disease Prevalence
12.7.2.3. Regulatory Framework
12.7.2.4. Reimbursement Framework
12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.3. Argentina
12.7.3.1. Key Country Dynamics
12.7.3.2. Target Disease Prevalence
12.7.3.3. Regulatory Framework
12.7.3.4. Reimbursement Framework
12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8. Middle East and Africa
12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.2. South Africa
12.8.2.1. Key Country Dynamics
12.8.2.2. Target Disease Prevalence
12.8.2.3. Regulatory Framework
12.8.2.4. Reimbursement Framework
12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.3. Saudi Arabia
12.8.3.1. Key Country Dynamics
12.8.3.2. Target Disease Prevalence
12.8.3.3. Regulatory Framework
12.8.3.4. Reimbursement Framework
12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.4. UAE
12.8.4.1. Key Country Dynamics
12.8.4.2. Target Disease Prevalence
12.8.4.3. Regulatory Framework
12.8.4.4. Reimbursement Framework
12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.5. Kuwait
12.8.5.1. Key Country Dynamics
12.8.5.2. Target Disease Prevalence
12.8.5.3. Regulatory Framework
12.8.5.4. Reimbursement Framework
12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 13. Competitive Landscape
13.1. Participant Overview
13.2. Company Market Position Analysis
13.3. Company Categorization
13.4. Strategy Mapping
13.5. Company Profiles/Listing
13.5.1. F. Hoffmann-La Roche Ltd
13.5.1.1. Overview
13.5.1.2. Financial Performance
13.5.1.3. Product Benchmarking
13.5.1.4. Strategic Initiatives
13.5.2. Novartis AG
13.5.2.1. Overview
13.5.2.2. Financial Performance
13.5.2.3. Product Benchmarking
13.5.2.4. Strategic Initiatives
13.5.3. AbbVie Inc.
13.5.3.1. Overview
13.5.3.2. Financial Performance
13.5.3.3. Product Benchmarking
13.5.3.4. Strategic Initiatives
13.5.4. Johnson & Johnson Services, Inc.
13.5.4.1. Overview
13.5.4.2. Financial Performance
13.5.4.3. Product Benchmarking
13.5.4.4. Strategic Initiatives
13.5.5. Merck & Co., Inc.
13.5.5.1. Overview
13.5.5.2. Financial Performance
13.5.5.3. Product Benchmarking
13.5.5.4. Strategic Initiatives
13.5.6. Pfizer Inc.
13.5.6.1. Overview
13.5.6.2. Financial Performance
13.5.6.3. Product Benchmarking
13.5.6.4. Strategic Initiatives
13.5.7. Bristol-Myers Squibb Company
13.5.7.1. Overview
13.5.7.2. Financial Performance
13.5.7.3. Product Benchmarking
13.5.7.4. Strategic Initiatives
13.5.8. Sanofi
13.5.8.1. Overview
13.5.8.2. Financial Performance
13.5.8.3. Product Benchmarking
13.5.8.4. Strategic Initiatives
13.5.9. GSK plc.
13.5.9.1. Overview
13.5.9.2. Financial Performance
13.5.9.3. Product Benchmarking
13.5.9.4. Strategic Initiatives
13.5.10. AstraZeneca
13.5.10.1. Overview
13.5.10.2. Financial Performance
13.5.10.3. Product Benchmarking
13.5.10.4. Strategic Initiatives
13.5.11. Takeda Pharmaceutical Company Limited
13.5.11.1. Overview
13.5.11.2. Financial Performance
13.5.11.3. Product Benchmarking
13.5.11.4. Strategic Initiatives
13.5.12. Biogen
13.5.12.1. Overview
13.5.12.2. Financial Performance
13.5.12.3. Product Benchmarking
13.5.12.4. Strategic Initiatives
13.5.13. Eli Lilly and Company
13.5.13.1. Overview
13.5.13.2. Financial Performance
13.5.13.3. Product Benchmarking
13.5.13.4. Strategic Initiatives
13.5.14. Novo Nordisk A/S
13.5.14.1. Overview
13.5.14.2. Financial Performance
13.5.14.3. Product Benchmarking
13.5.14.4. Strategic Initiatives
13.5.15. Amgen Inc.
13.5.15.1. Overview
13.5.15.2. Financial Performance
13.5.15.3. Product Benchmarking
13.5.15.4. Strategic Initiatives
°ü·ÃÀÚ·á